IU Alzheimer’s study to be funded by $8.4M federal grant

An $8.4 million stimulus grant will fund a comparison study of three Alzheimer’s drugs at central Indiana memory care centers.

The study will enroll 300 Hoosier patients and give them one of three Alzheimer’s drugs: Aricept, Exelon or Reminyl. Led by Dr. Malaz Boustani of the Indiana University School of Medicine, the study will attempt to show which of the drugs proves most effective compared with the others.

Remaining money from the federal grant will be invested to beef up the infrastructure of the Indiana Network for Patient Care, a health information exchange operated by the Indianapolis-based Regenstrief Institute.

The network serves as the backbone of the Indiana Health Information Exchange, which has linked up physicians and hospitals around Indiana to share patient medical records electronically.

The grant, funded by the 2009 American Recovery and Reinvestment Act, was awarded by the federal Agency for Healthcare Research and Quality.

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.